acamprosate vs esketamine
Side-by-side comparison of acamprosate and esketamine Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Spravato
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Spravato is a nasal spray medicine used to treat depression. It contains esketamine and affects certain receptors in the brain.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Spravato is used to treat treatment-resistant depression in adults. This is when other antidepressant medicines have not worked well enough. It can also treat depressive symptoms in adults with major depressive disorder who are having suicidal thoughts or behaviors. Spravato is used along with an oral antidepressant.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Spravato is a type of medicine called an NMDA receptor antagonist. It works by affecting certain receptors in the brain. These receptors are involved in regulating mood and emotions.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Feeling disconnected from yourself or your surroundings
- • Dizziness
- • Nausea
- • Sleepiness
- • Spinning sensation
- Low blood pressure 14
- Weakness 13
- Condition worsened 13
- Using the medicine for something it is not approved for 13
- Sudden kidney damage 12
- Feeling disconnected from yourself or your surroundings 3,351
- Sleepiness 2,465
- Thoughts of suicide 1,233
- The medicine is not working 1,032
- Feeling sick to your stomach 876
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Spravato can cause sleepiness, feeling disconnected, and breathing problems. You will be monitored for these side effects. Spravato has the potential for abuse and misuse. Spravato may increase suicidal thoughts and behaviors in young adults. Spravato is only available through a special program.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Spravato may harm an unborn baby. Talk to your doctor about pregnancy planning and birth control. Breastfeeding is not recommended while using Spravato.
How to Read This acamprosate vs esketamine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while esketamine sits within the NMDA Receptor Antagonist (Nasal Spray) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 65 submissions while esketamine has 8,957. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between acamprosate and esketamine — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.